Date:Mar. 25, 2021
Your Name: Wei Li
Manuscript Title:_ Artesunate attenuates proliferation of epithelial cells by downregulating the NF-кВ and АКТ
signaling pathways in benign mammary gland hyperplasia rats
Manuscript number (if known): ATM-21-1447

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	_vNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	vNone	
3	Royalties or licenses	vNone	
4	Consulting fees	VNone	

	1	Т		
5	Payment or honoraria for	VNone		
	lectures, presentations,			
	speakers bureaus,			
	manuscript writing or			
	educational events			
6	Payment for expert	v None		
	testimony			
7	Support for attending	vNone		
	meetings and/or travel			
8	Patents planned, issued or	vNone		
	pending			
9	Participation on a Data	vNone		
	Safety Monitoring Board or			
	Advisory Board			
10	Leadership or fiduciary role	v None		
	in other board, society,			
	committee or advocacy			
	group, paid or unpaid			
11	Stock or stock options	vNone		
12	Receipt of equipment,	_vNone		
	materials, drugs, medical			
	writing, gifts or other			
13	services Other financial or non-	√ None		
13	financial interests	v_None		
	illialiciai liiterests			
Dla	ase summarize the above co	unflict of interest in the fo	llowing hove	
FIE	ase summarize the above to	minet of interest in the lo	nowing box.	
Т	There is no conflict of interest to declare.			
'	There is no commet of interest to	, acciarc.		
- 1				

Date:Mar. 25, 2021
Your Name: Lina Zhao
Manuscript Title:_ Artesunate attenuates proliferation of epithelial cells by downregulating the NF-κB and AKT
signaling pathways in benign mammary gland hyperplasia rats
Manuscript number (if known): ATM-21-1447

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Time frame: Since the initialVNone	planning of the work
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	vNone	
3	Royalties or licenses	vNone	
4	Consulting fees	VNone	

5	Payment or honoraria for	_vNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	√None	
	testimony		
7	Support for attending	√None	
	meetings and/or travel		
0	Datanta planned issued or	n/ None	
8	Patents planned, issued or pending	vNone	
	pending		
9	Participation on a Data	√ None	
9	Safety Monitoring Board or	vnone	
	Advisory Board		
10	Leadership or fiduciary role	√ None	
10	in other board, society,	vnone	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	√ None	
11	Stock of Stock options		
12	Receipt of equipment,	√ None	
12	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	√ None	
	financial interests		
Plea	ase summarize the above co	onflict of interest in the	following box:
	ase summarize the above to	minet of interest in the	ionowing work
Т	here is no conflict of interest to	n declare	
'	o is no commet of interest to		
- 1			

Date:Mar. 25, 2021
Your Name: Yiliang Li
Manuscript Title:_ Artesunate attenuates proliferation of epithelial cells by downregulating the NF-кВ and АКТ
signaling pathways in benign mammary gland hyperplasia rats
Manuscript number (if known): ATM-21-1447

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Time frame: Since the initialVNone	planning of the work
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	vNone	
3	Royalties or licenses	vNone	
4	Consulting fees	VNone	

5	Payment or honoraria for lectures, presentations,	_vNone	
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	√ None	
U	testimony	vNone	
	testimony		
_	0 16 11		
7	Support for attending	VNone	
	meetings and/or travel		
8	Patents planned, issued or	√ None	
	pending		
	pending		
0	Dantisia atian an a Data	a/ Nama	
9	Participation on a Data	vNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	√None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	vNone	
12	Receipt of equipment, materials, drugs, medical	√ None	
	writing, gifts or other		
	services		
13	Other financial or non-	√ None	
	financial interests		
Dlo	ase summarize the above co	nflict of interest in the fe	llowing hove
FIE	ase summanize the above to	וווווכנ טו ווונפופגנ ווו נוופ ול	mowing box.
_	There is no conflict of interest to declare.		
'	nere is no conflict of interest to	declare.	

Date:Mar. 25, 2021		
Your Name: <u>Zhen Zhai</u>		
Manuscript Title: Artesunate attenuates proliferation of epithelial cells by downregulating the NF-κB and AKT		
signaling pathways in benign mammary gland hyperplasia rats		
Manuscript number (if known): ATM-21-1447		

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Time frame: Since the initialVNone	planning of the work
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	vNone	
3	Royalties or licenses	vNone	
4	Consulting fees	VNone	

			<u> </u>
5	Payment or honoraria for	_vNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	vNone	
	testimony		
7	Support for attending meetings and/or travel	vNone	
8	Patents planned, issued or	vNone	
	pending		
9	Participation on a Data	VNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	VNone	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid	/ 21	
11	Stock or stock options	vNone	
12	Descript of a surjement	of Name	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other	VNone	
	services		
13	Other financial or non-	√ None	
10	financial interests		
	nse summarize the above co		following box: